175 related articles for article (PubMed ID: 34310614)
1. Cost-effectiveness of dengue vaccination in Puerto Rico.
España G; Leidner AJ; Waterman SH; Perkins TA
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009606. PubMed ID: 34310614
[TBL] [Abstract][Full Text] [Related]
2. Public health impact and cost-effectiveness of implementing a 'pre-vaccination screening' strategy with the dengue vaccine in Puerto Rico.
Thommes E; Coudeville L; Muhammad R; Martin M; Nelson CB; Chit A
Vaccine; 2022 Nov; 40(50):7343-7351. PubMed ID: 36347720
[TBL] [Abstract][Full Text] [Related]
3. Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.
España G; Yao Y; Anderson KB; Fitzpatrick MC; Smith DL; Morrison AC; Wilder-Smith A; Scott TW; Perkins TA
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007482. PubMed ID: 31260441
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
[TBL] [Abstract][Full Text] [Related]
5. Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation.
Adams LE; Hitchings MDT; Medina FA; Rodriguez DM; Sánchez-González L; Moore H; Whitehead SS; Muñoz-Jordán JL; Rivera-Amill V; Paz-Bailey G
Am J Trop Med Hyg; 2023 Aug; 109(2):413-419. PubMed ID: 37308104
[TBL] [Abstract][Full Text] [Related]
6. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
Lee JS; Lourenço J; Gupta S; Farlow A
Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dengue vaccination in ten endemic countries.
Zeng W; Halasa-Rappel YA; Baurin N; Coudeville L; Shepard DS
Vaccine; 2018 Jan; 36(3):413-420. PubMed ID: 29229427
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
Shim E
Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
[TBL] [Abstract][Full Text] [Related]
9. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
[TBL] [Abstract][Full Text] [Related]
10. Serostatus testing and dengue vaccine cost-benefit thresholds.
Pearson CAB; Abbas KM; Clifford S; Flasche S; Hladish TJ
J R Soc Interface; 2019 Aug; 16(157):20190234. PubMed ID: 31431184
[TBL] [Abstract][Full Text] [Related]
11. The seroepidemiology of dengue in a US military population based in Puerto Rico during the early phase of the Zika pandemic.
Pollett S; Kuklis CH; Barvir DA; Jarman RG; Romaine RM; Forshey BM; Gromowski GD
PLoS Negl Trop Dis; 2022 Jan; 16(1):e0009986. PubMed ID: 35061659
[TBL] [Abstract][Full Text] [Related]
12. Epidemiologic Trends of Dengue in U.S. Territories, 2010-2020.
Ryff KR; Rivera A; Rodriguez DM; Santiago GA; Medina FA; Ellis EM; Torres J; Pobutsky A; Munoz-Jordan J; Paz-Bailey G; Adams LE
MMWR Surveill Summ; 2023 May; 72(4):1-12. PubMed ID: 37192141
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
14. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
[TBL] [Abstract][Full Text] [Related]
15. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
Flasche S; Jit M; Rodríguez-Barraquer I; Coudeville L; Recker M; Koelle K; Milne G; Hladish TJ; Perkins TA; Cummings DA; Dorigatti I; Laydon DJ; España G; Kelso J; Longini I; Lourenco J; Pearson CA; Reiner RC; Mier-Y-Terán-Romero L; Vannice K; Ferguson N
PLoS Med; 2016 Nov; 13(11):e1002181. PubMed ID: 27898668
[TBL] [Abstract][Full Text] [Related]
16. Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees.
Velumani S; Toh YX; Balasingam S; Archuleta S; Leo YS; Gan VC; Thein TL; Wilder-Smith A; Fink K
Hum Vaccin Immunother; 2016 May; 12(5):1265-73. PubMed ID: 26889737
[TBL] [Abstract][Full Text] [Related]
17. Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.
Rodriguez DM; Major CG; Sánchez-González L; Jones E; Delorey MJ; Alonso C; Rivera-Amill V; Paz-Bailey G; Adams LE
Vaccine; 2023 Jun; 41(24):3627-3635. PubMed ID: 37173267
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia.
Suwantika AA; Supadmi W; Ali M; Abdulah R
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009664. PubMed ID: 34383764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
